GlassScriptPhysician profile
Michael A Loden
NPI 1922089382
$1,774.17
in general payments reported to CMS, 2019-2025
24 companies · $390 in 2025
The $390 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $791 · 2021: $111 · 2022: $50.41 · 2023: $104 · 2024: $328 · 2025: $390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $822.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $822.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $303.37 | 2019-2025 | |
| Novo Nordisk INC | $256.30 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $181.76 | 2019-2024 | Arexvy, Shingrix |
| Abbvie INC. | $179.39 | 2023-2025 | |
| Astellas Pharma US INC | $169.67 | 2019-2025 | Veozah |
| Allergan, INC. | $140.36 | 2019 | |
| Amgen INC. | $96.77 | 2022-2025 | Otezla, Repatha, Evenity |
| Supernus Pharmaceuticals, INC. | $85.38 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $44.90 | 2019 | |
| Sunovion Pharmaceuticals INC. | $43.54 | 2019 | |
| Dexcom, INC. | $34.64 | 2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Janssen Pharmaceuticals, INC | $31.04 | 2019 | |
| Lilly USA, LLC | $27.68 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $26.95 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $21.43 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $17.67 | 2019 | |
| Organon LLC | $17.07 | 2024-2025 | Nexplanon |
| Otsuka America Pharmaceutical, INC. | $16.82 | 2023 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $15.90 | 2024 | |
| Aimmune Therapeutics, INC. | $15.18 | 2025 | Zenpep |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.93 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.38 | 2021 | |
| Merck Sharp & Dohme LLC | $11.44 | 2019 | |
| Phathom Pharmaceuticals, INC. | $9.60 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Loden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.